

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

JC17 Rec'd PCT/PTO 16 JUN 2005

1. (Original) Use of a CD137 antagonist for the preparation of a medicament for the treatment of CD137-expressing tumors.
2. (Original) Use according to claim 1 wherein the CD137 antagonist is selected from the group consisting of a CD137-specific antibody, peptide, organic small molecule, antisense oligonucleotide, siRNA, antisense expression vector or recombinant virus.
3. (Currently Amended) Use according to claim 1 or 2 wherein the antibody is directed to at least one epitope of the amino acid sequence of human CD137 shown in Fig. 8B.
4. (Original) Use according to claim 3 wherein the CD137-specific antibody is clone BBK- 2 or clone 4B4-1.
5. (Original) Use according to claim 2 wherein the CD137-specific antisense expression vector is RSV-ILA-AS.
6. (Original) Use according to claim 1 wherein the CD137 antagonist is selected from the group consisting of a CD137 ligand-specific antibody, peptide, organic small molecule, antisense oligonucleotide, siRNA, antisense expression vector or recombinant virus.
7. (Currently Amended) Use according to claim 1 ~~any one of claims 1 to 6~~ wherein the tumor is a B cell lymphoma, tumor of the vulva, neuroblastoma, cystadenocarcinoma of the ovary, rhabdomyosarcoma, leiomyosarcoma, fibrosarcoma, immunocytoma, non-Hodgkin lymphoma, carcinoma of the portio uteri or basal cell carcinoma.

8. (Original) Use according to claim 7 wherein the B cell lymphoma is chronic lymphocytic leukaemia.
9. (Original) Method of treating a tumor patient comprising administering an effective amount of a CD137 antagonist.
10. (Currently Amended) Method according to ~~claim 9~~ ~~claim 8~~ wherein the CD137 antagonist is selected from the group consisting of a CD137-specific antibody, peptide, organic small molecule, antisense oligonucleotide, siRNA, antisense expression vector or recombinant virus as defined in any one of claims 2 to 6.
11. (Currently Amended) Method according to ~~claim 9 or 10~~ wherein the tumor is a B cell lymphoma, tumor of the vulva, nephroblastoma, cystadenocarcinoma of the ovary, rhabdomyosarcoma, leiomyosarcoma, fibrosarcoma, immunocytoma, nonHodgkin lymphoma, carcinoma of the portio uteri or basal cell carcinoma.
12. (Original) Method according to claim 11 wherein the B cell lymphoma is chronic lymphocytic leukaemia.
13. (Original) Use of CD137 or a functional analogue or derivative thereof for the preparation of a medicament for the treatment of conditions characterised by undesired or overactive immune responses.
14. (Original) Use according to claim 13 wherein the CD137 or functional analogue or derivative is encoded by a nucleic acid comprising a nucleotide sequence having at least 90% homology to the coding sequence shown in Fig. 8A.

15. (Original) Use according to claim 14 wherein the CD 137 has the amino acid sequence shown in Fig. 8B.
16. (Currently Amended) Use according to claim 13 ~~any one of claims 13 to 15~~ wherein the condition is selected from autoimmune diseases, allergies, asthma and organ transplant rejection.
17. (Original) Use of an agonistic anti-CD137 ligand antibody for the preparation of a medicament for the treatment of conditions characterised by undesired or overactive immune responses.
18. (Original) Use according to claim 17 wherein the condition is selected from autoimmune diseases, allergies, asthma and organ transplant rejection.
19. (Original) Method for treating a patient suffering from a condition characterised by undesired or overactive immune responses comprising administering an effective amount of CD137 or a functional analogue or derivative thereof and/or an agonistic anti-CD137 ligand antibody.
20. (Currently Amended) Method of claim 19 wherein the CD137 ~~is as defined in claim 14 or 15~~ or functional analogue or derivative thereof is encoded by a nucleic acid comprising a nucleotide sequence having at least 90% homology to the coding sequence shown in Fig. 8A.
21. (Currently Amended) Method of claim 19 ~~or 20~~ wherein the condition is selected from autoimmune diseases, allergies, asthma and organ transplant rejection.

22. (New) Method according to claim 9 wherein the CD137 antagonist is an antibody directed to at least one epitope of the amino acid sequence of human CD137 shown in Fig. 8B.
23. (New) Method according to claim 9 wherein the CD137 antagonist is clone BBK- 2 or clone 4B4-1
24. (New) Method according to claim 9 wherein the CD137 antagonist is the antisense expression vector RSV-ILA-AS.
25. (New) Method according to claim 9 wherein the CD137 antagonist is selected from the group consisting of a CD137 ligand-specific antibody, peptide, organic small molecule, antisense oligonucleotide, siRNA, antisense expression vector or recombinant virus.
26. (New) Method of claim 20 wherein the CD137 has the amino acid sequence shown in Fig. 8B.